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The murine mammary FM3A/O and the thymidylate (dTMP) synthetase-deficient FM3A/TS- carcinoma 
cell lines can be considered as a novel and useful test system for the detection of nucleoside analogues 
which are directly aimed at the thymidylate synthetase. These compounds hould be inhibitory for 
FM3A/O but not for FM3A/TS cells, and their inhibitory effects on FM3A/O cell growth shoutd be 
readily reversed by exogenous dThd within the concentration range of S-2C FM. 
Murine mammary FM3A carcinoma Thymidylate synthetase T-Substituted 2 ‘-deoxyuridine analog 
1. INTRODUCTION and (iii) tritium release from [5-3H]dUrd or 
[5-3H]dCyd [I&21]. 
A broad variety of nucleoside analogues have We propose here a novel system for the evalua- 
been developed as potential antitumor agents, and tion and detection of dTMP synthetase inhibitors. 
the biochemical basis of their cytostatic action has This system is based upon the use of a murine 
been extensively studied using murine leukemia FM3A mammary carcinoma FM3A/O cell line and 
L1210 cells as a test system. 5-Substituted its dTMP synthetase-deficient subline FM3A/TS. 
2 ’ -deoxyuridines such as 5-fluoro-dUrd [l-4], For a series of twenty 5-substituted 2’-deoxyuri- 
S-trifluoromethyl-dUrd [ 1,5,6], S-nitro-dUrd dines there was a close correlation between their 
[ 1,7,8] and 5-formyl-dUrd [ 1,9, lo] suppress tumor inhibitory effects on FM3A/O cell growth and 
cell proliferation by inhibition of thymidylate their inhibitory effects on L1210 cell growth (r = 
(dTMP) synthetase. This enzyme is pivotal for the 0.986). For those compounds that exerted their 
de novo biosynthesis of DNA and can, therefore, cytostatic activity by an inhibitory effect at the 
be regarded as an attractive target for cancer dTMP synthetase level, viz., 5-fluoro-dUrd, 5-tri- 
chemotherapy. Not surprisingly, its activity is fluoromethyl-dUrd, 5-nitro-dUrd, S-ethynyl-dUrd 
substantially elevated in proliferating cells, as com- and 5-formyl-dUrd, addition of exogenous dThd 
pared to normal tissues [ll]. The interaction of brought about a pronounced reversal of the 
pyrimidine nucleoside analogues with thymidylate FM3A/O cell growth-inhibiting effects. This rever- 
synthetase has been investigated either directly sal was dose-dependent within the dThd concentra- 
with isolated or purified enzyme preparations tion range 5-20 /IM. The FM3AITS cells did not 
[12-171 or indirectly in intact cells, by measuring grow in the absence of dThd, and when assayed in 
(i) the differential incorporation of radiolabelled the presence of 5 or 20pM dThd, none of the 
dUrd and dThd into DNA [l], (ii) the reversal of aforementioned 5-substituted 2’-deoxyuridines ex- 
the cell growth inhibition by dUrd and dThd [I], erted a marked inhibitory effect on the growth of 
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FM3A/TS- cells. This observation corroborates 
the hypothesis that the cytostatic action of 5-sub- 
stituted 2’-deoxyuridines such as 5-fluoro-dUrd, 
5-trifluoromethyl-dUrd, etc. is primarily targeted 
at the dTMP synthetase level. 
2. MATERIALS AND METHODS 
2.1. Cells 
Mouse leukemia L1210 cells were grown in 
75cm2 tissue culture flasks (Sterilin, Teddington, 
England) in Eagle’s minimal essential medium, 
supplemented with 10% (v/v) inactivated foetal 
calf serum (Gibco Bio-Cult, Glasgow, Scotland), 
2 mM L-glutamine (Flow Laboratories, Irvine, 
Scotland) and 0.075% (w/v) NaHCOs (Flow 
Laboratories). 
Mouse FM3A cells (subclone F28-7), originally 
established from a spontaneous mammary car- 
cinoma in a C3H/He mouse [22,23] and 
designated FM3A/O, were grown in the same 
culture medium as the L1210 cells. A FM3A 
subclone (designated FM3A/TS) was also main- 
tained in this culture medium, but supplemented 
with 20 FM dThd [24]. 
2.2. Chemicals 
The sources of the compounds were as follows: 
5-fluoro-dUrd (Aldrich, Milwaukee, WI); 5-triflu- 
oromethyl-dUrd (P.-L. Biochemicals, Milwaukee, 
WI); 5-nitro-dUrd (provided by M.J. Robins, 
Edmonton, Canada); 5-ethynyl-dUrd [25,26], 
5-formyl-dUrd [27], 5-hydroxymethyl-dUrd (Cal- 
biochem-Behring, Lucerne), 5-vinyl-dUrd [26], 
Q-5-(2-iodovinyl)-dUrd [26], (Q-5-(2-bromovin- 
yl)-dUrd [26,28], 5-ethyl-dUrd [29,30], 5-azido- 
2methyl-dUrd [3 1,321, 5-cyano-dUrd [33], Q-5- 
(Zchlorovinyl)-dUrd [26], 5-methylthiomethyl- 
dUrd [32,34], 5-(1,3-dithiolan-2-yl)-dUrd [27], 
5-propyl-dUrd [35], 5-methylsulfinylmethyl-dUrd 
[34], 5-hydroxy-dUrd (Sefochem, Emek Hayar- 
den, Israel), 5-propynyloxy-dUrd [36], dUrd 
(Sigma, MO), dThd (Sigma). 
2.3. Inhibition of tumor cell growth 
All assays were performed in microtest plates 
(Sterilin). To each well were added 5 x lo4 L1210, 
FM3A/O or FM3A/TS cells and a given amount 
of the test compound. In those assays that were 
228 
aimed at evaluating the effects of dThd, 5 or 
20pM dThd was added to the cells together with 
varying amounts of the test compound. The doses 
used for dThd (5 and 20 PM) corresponded to their 
capacity to sustain normal growth of the 
FM3A/TS- cells during 24 and 48 h, respectively. 
The cells were allowed to proliferate for 24 and 
48 h at 37°C in a humidified, COz-controlled at- 
mosphere. At the end of the incubation period, the 
cells were counted in a Coulter Counter (Coulter 
Electronics, Harpenden, England). 
3. RESULTS AND DISCUSSION 
3.1. Comparison of the FM3A/O and L1210 cell 
systems for the evaluation of the inhibitory 
effects of Ssubstituted 2 ‘-deoxyuridines on 
cell proliferation 
The 5-substituted 2’-deoxyuridines were ex- 
amined at a variety of concentrations (1 ng/ml to 
1 mg/ml) for their inhibitory effects on FM3A/O 
cell proliferation, and the ZDSO values (inhibitory 
dose-50, or dose required to inhibit cell prolifera- 
tion by 50%) are presented in table 1. There were 
marked differences in the inhibitory effects of the 
5-substituted 2’-deoxyuridines on FM3A/O cell 
growth. With an IDso of 1 ng/ml, 5-fluoro-dUrd 
was the most potent, and with an IDSO of 
> 1 mg/ml, 5-propyl-, 5-propynyloxy-, 5-hydroxy- 
and 5-methylsulfinylmethyl-dUrd were the least 
potent agents. The other compounds showed IDso 
values that were intermediate between these two 
extremes. Clearly, when compared with the ZDso 
values previously found for L1210 cell prolifera- 
tion [ 1,371, the most potent inhibitors of FM3A/O 
cell growth (with an IDSO < 1 pg/ml), viz., 
5-fluoro-dUrd, 5-trifluoromethyl-dUrd, 5-nitro- 
dUrd, 5-ethynyl-dUrd and 5-formyl-dUrd, were 
also the most inhibitory to L1210 cell growth 
(fig.1); and those compounds that were inactive as 
inhibitors of FM3A/O cell growth were also inac- 
tive against L1210 cells. In general, the IDSO values 
for the mouse mammary FM3A/O carcinoma cells 
corresponded closely to the Z&r values for L1210 
cells, except for Q-5-(2-iodovinyl)-dUrd and 
5-cyano-dUrd, which were about 5-7-times more 
inhibitory to FM3A/O cells. For the 20 dUrd 
analogues that were evaluated for inhibition of 
tumor cell growth there appeared to be a strong 
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Inhibitory effects of 5-substituted 2’-deoxyuridine derivatives on the proliferation of FM3A/O cells 
No. Comnound ID50a &g/ml) for FM3A/O cell proliferation 
As such Upon addition of 
5 pM dThd 
Upon addition of 
20pM dThd 
1 5-fluoro-dUrd 
2 5-trifluoromethyl-dUrd 
3 5-nitro-dUrd 
4 5-ethynyl-dUrd 
5 5-formyl-dUrd 
6 5-hydroxymethyl-dUrd 
7 5-vinyl-dUrd 
8 (Q-5-(2-iodovinyl)-dUrd 
9 (E)-5-(2-bromovinyl)-dUrd 
10 5-ethyl-dUrd 
11 5-azidomethyl-dUrd 
12 5-cyano-dUrd 
13 (E)-5-(2-chlorovinyl)-dUrd 
14 5-methylthiomethyl-dUrd 
15 5-( 1,3-dithiolan-2-yl)-dUrd 
16 5-propyl-dUrd 
17 5-methylsulfinylmethyl-dUrd 
18 5-hydroxy-dUrd 
19 5-propynyloxy-dUrd 
20 dUrd 
0.001 ( f 0.0003) 
0.013 (&0.007) 
0.013 ( f 0.003) 
0.131 (&0.005) 
0.171 (kO.062) 
2.0 (kO.3) 
2.0 (kO.65) 
4.0 (kO.91) 
11 (* 5.07) 
0.030 ( f 0.02) 
0.088 ( f 0.013) 
0.045 (* 0.022) 
0.790 (* 0.010) 
1.5 (kO.54) 
55 (k4.6) 
28 (* 14.3) 
201 (254) 
380 ( + 227) 
12 
26 
30 
184 
420 
537 
>lOOO 
>lOOO 
>lOOO 
>lOOO 
>I000 
(* 0.02) 554 
( f 2.0) 64 
(k4.61) 268 
(k27) 290 
(250) 349 
(* 153) 587 
>lOOO 
>lOOO 
> 1000 
> 1000 
> 1000 
124 (k56) 
180 (230) 
>lOOO 
152 (+96) 
150 (*78) 
351 (+45) 
252 (+118) 
315 (+31) 
529 ( + 197) 
(+136) >lOOO 
(+ 13) 62 ( 
(2 17) >lOOO 
(k39) 573 
(+86) 507 
(&47) >lOOO 
>lOOO 
>lOOO 
>lOOO 
>lOOO 
>lOOO 
f 18) 
+ 97) 
* 36) 
a Inhibitory dose-50, + SD 
I 1 1 
Y = 0927X- 0 161 
r = 0 986 
-3 -2 -1 0 1 2 3 
log ID,, for L 1210 cell prollferatlon Iygg/mll 
Fig. 1. Correlation between the log ID50 of 5-substituted 
2’-deoxyuridines for L1210 cell proliferation and their 
log IDS,-, for FM3A/O cell proliferation. The 1050 values 
for L1210 cell proliferation are taken from [l]. The 
symbols for the compounds are indicated in table 1. 
linear correlation (r = 0.986) between the log IDso 
for FM3A/O cell growth and that for L1210 cell 
growth (fig.1). Thus, from the results obtained 
with a given Ssubstituted 2’ -deoxyuridine in the 
mouse mammary FM3A/O carcinoma system, one 
might readily predict its inhibitory activity for 
murine leukemia L1210 cells and vice versa. Also, 
the L1210 and FM3A/O cell lines showed similar 
IDSO values for other antitumor agents such as 
cytosine arabinoside, Sfluorouracil and metho- 
trexate (not shown). Therefore, FM3A/O cells 
may be considered as a valuable system for the 
evaluation of compounds with potential antitumor 
activity. Moreover, when lo6 FM3A/O cells were 
injected intraperitoneally into CJH/He mice, the 
median life span of the mice was about 17 days, as 
compared to 6 days for DBA/2 mice inoculated 
with murine leukemia L1210 cells and 11 days for 
DBA/2 mice inoculated with murine leukemia 
P388 cells. Thus, the murine mammary (FM3A) 
carcinoma model can also be advocated for the in 
vivo evaluation of antitumor agents. 
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3.2. Inhibitory effects of j-substituted 2 ‘-deoxy- 
uridines on the proliferution of FA43A/O and 
FM3AITS cefls in the presence of thy~idine 
Recently, a dTMP synth~tase-deficient mutant 
cell line was derived from mutagenised mouse 
FM3A carcinoma cells [22,23]. This mutant cell 
line resulted from a genetic defect in dTMP syn- 
thetase and proved to be very stable. Less than I % 
of dTMP synthetase activity was detected in the 
mutant FM3AITS cells, as compared to the 
parent wild-type FM3A/O cells [24]. However, 
there was no substantial difference between the 
dUrd kinase and dThd kinase activities of 
FM3A/O and FM3A/TS cells [24]. Since the 
FM3A/TS cell line was auxotrophic for dThd 
124,381, it did not grow unless exogenous dThd was 
supplied [24]. For normal cell growth 20 yM dThd 
was required; 5 FM dThd only enabled the cells to 
proliferate for 24 h, whereafter cell growth 
reached the stationary growth phase [24]. This 
means that to evaluate the inhibitory effects of 
Gzubstituted 2’ -deoxyuridines on FM3AITS cell 
growth, dThd had to be added to the cell culture 
medium. Two different concentrations (5 and 
20 $M) of dThd were used, and both FM3A/O and 
FM3A/TS cells were assayed for the sensitivity to 
the growth-inhibitory effects of 5-substituted 
2’-deoxyuridines in the presence of these dThd 
concentrations. 
For those compounds, which are assumed to in- 
teract at the dTMP synthetase level, viz. com- 
pounds l-5, there was a marked difference bet- 
ween their IDso values for FM3A/O cell growth 
upon addition of 5 pM dThd and those upon addi- 
tion of 20pM dThd (table 1). The ratio between 
these IDSO values was as great as 2000 for 
5-trifluoromethyl-dUrd, 4000 for 5-fluoro-dUrd 
and >20000 for 5-nitro-dUrd. No such differences 
Table 2 
Inhibitory effects of 5-substituted 2’-deoxyuridine derivatives on the proliferation of FM3A/TS cells 
No. Compound ID50a @g/ml) for FM3A/TS- cell proliferation 
Upon addition of Upon addition of 
5 FM dThd 20pM dThd 
1 5-fluoro-dUrd 159 (&91) 91 (ts.5) 
2 5-trifluoromethyl-dUrd 25 (k15) 167 (+53) 
3 S-nitro-dUrd >lOOO > 1000 
4 S-ethynyi-dUrd >lOO >lOO 
5 5-formyl-dUrd 270 (+33) 270 (+S) 
6 S-hydroxymethyl-dUrd 60 (+25) 316 (rt:35) 
7 S-vinyl-dUrd 203 ( rf: 168) 271 (+40) 
8 (I+5-(2-iodovinyl)-dUrd 255 (?72) 258 (k34) 
9 (.!I?)-5-(2-bromovinyl)-dUrd 297 (k7.9) 373 (LtllO) 
10 5-ethyl-dUrd 734 (* 19) >lOOO 
11 S-~idomethyl-dUrd 171 f&90) 40 (17) 
12 S-cyano-dUrd >lOOO >lOOO 
13 (I?)-5-(2-chforovinyl)-dUrd 226 (+41) 507 (285) 
14 S-methylthiomethyl-dUrd 269 (k86) 398 (+31) 
15 5-( 1,3-dithiolan-2-yl)-dUrd 375 (* 193) 648 ( rt 140) 
16 5-propyl-dUrd 427 (+-46) > 1000 
17 5-methylsulfinylmethyl-dUrd > 1000 >I000 
18 5-hydroxy-dUrd >lOOO >lOOO 
19 S-propynyloxy-dUrd >lOOO > 1000 
20 dUrd > 1000 > 1000 
a Inhibitory dose-50; ~?r SD 
The I&, values of the compounds as such (in the absence of dThd) could not be determined since the 
FM3A/TS- cells did not proliferate in the absence of dThd 
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were found in the ZDSO values for FM3A/TS upon 
addition of 5 FM dThd and 20pM dThd, respec- 
tively (table 2). In fact, none of the 5substituted 
2 ’ -deoxyuridines exerted a pronounced inhibitory 
effect on FM3A/TS- cell growth, irrespective of 
the dThd concentration used. The fact that com- 
pounds 1-5, while strongly inhibitory to FM3A/O 
cells, were virtually inactive against FM3A/TS- 
cells, combined with the observation that their in- 
hibitory effect on FM3A/O cell growth was re- 
versed by dThd in a dose-dependent fashion, clear- 
ly indicates that these compounds are targeted at 
the dTMP synthetase level. 
The cytostatic effects of compounds 6-10 were 
also reversed upon the addition of 5 pM dThd 
(14-50-fold); but only a slight increment in the 
reversal ratio was observed by further increasing 
the dThd concentration to 20 PM. As noted in [l], 
addition of dUrd considerably reversed the 
cytostatic effects of compounds 6-10, whereas ad- 
dition of dThd caused only a slight further 
decrease in the inhibitory effects of these com- 
pounds on cell proliferation. For 5substituted 
2’ -deoxyuridines to qualify as inhibitors of dTMP 
synthetase, addition of dThd should give a 
significantly greater reversal of the tumor growth- 
inhibiting effects than addition of dUrd [ 11. This is 
clearly the case for compounds l-5 but not for 
compounds 6-10. Therefore, the latter cannot be 
considered as truly specific or potent inhibitors of 
dTMP synthetase, and this conclusion is further 
borne out by the results obtained here. 
As a rule, none of the 5-substituted 
2’-deoxyuridines proved to be more inhibitory 
toward FM3A/TS- than FM3A/O cells. This is 
evident from a direct comparison of the ZDSO 
values of the compounds for FM3A/TS and 
FM3A/O cells in the presence of 5 and 20pM 
dThd, respectively (tables 1,2). 
In conclusion, the murine mammary FM3A car- 
cinoma (FM3A/O-FM3A/TS-) cell lines can be 
considered as a novel and useful test system for the 
detection of thymidylate synthetase inhibiting 
nucleoside analogues. 
ACKNOWLEDGEMENTS 
This investigation was supported by grants from 
the Belgian Fonds voor Geneeskundig Weten- 
schappelijk Onderzoek (Krediet no.3.0048.75) and 
the Geconcerteerde Onderzoeksacties (Conventie 
no.81/86-27). We thank Miette Stuyck and Mar- 
leen Verstreken for excellent technical help and 
Christiane Callebaut for fine editorial assistance. 
REFERENCES 
Ill 
I21 
131 
141 
PI 
WI 
171 
181 
[91 
DOI 
[III 
(121 
1131 
1141 
WI 
iI61 
1171 
V81 
u91 
De Clercq, E., Balzarini, J., Torrence, P.F., 
Mertes, M.P., Schmidt, CL., Shugar, D., Barr, 
P.J., Jones, A.S., Verhelst, G. and Walker, R.T. 
(1981) Mol. Pharmacol. 19, 321-330. 
Hartman, K.U. and Heidelberger, C. (1961) J. 
Biol. Chem. 236, 30063013. 
Mathews, C.K. and Cohen, S.S. (1963) J. Biol. 
Chem. 238, 367-376. 
Blakley, R.L. (1963) J. Biol. Chem. 238, 
2113-2118. 
Reyes, P. and Heidelberger, C. (1965) Mol. 
Pharmacol. I, 14-30. 
Santi, D.V. and Sakai, T.T. (1971) Biochemistry 
10, 3598-3607. 
Wataya, Y., Matsuda, A. and Santi, D.V. (1980) J. 
Biol. Chem. 255, 5538-5544. 
Maggiora, L., Chang, C.T.-C., Torrence, P.F. and 
Mertes, M.P. (1981) J. Am. Chem. Sot. 103, 
3192-3198. 
Santi, D.V. and Sakai, T.T. (1971) Biochem. Bio- 
phys. Res. Commun. 42, 813-817. 
Santi, D.V. and Sakai, T.T. (1972) Biochem. Bio- 
phys. Res. Commun. 46, 1320-1325. 
Danenberg, P.V. (1977) Biochim. Biophys. Acta 
473, 73-92. 
Wataya, Y., Santi, D.V. and Hansch, C. (1977) J. 
Med. Chem. 20, 1469-1473. 
Matsuda, A., Wataya, Y. and Santi, D.V. (1978) 
Biochem. Biophys. Res. Commun. 84, 654-659. 
Reyes, P. and Heidelberger, C. (1965) Mol. 
Pharmacol. 1, 14-30. 
Schmidt, CL., Chang, CT.-C., De Clercq, E., 
Descamps, J. and Mertes, M.P. (1980) J. Med. 
Chem. 23, 252-256. 
Kampf, A., Barfknecht, R.L., Shaffer, P. J., 
Osaki, S. and Mertes, M.P. (1976) J. Med. Chem. 
19, 903-908. 
Balzarini, J., De Clercq, E., Mertes, M.P., Shugar, 
D. and Torrence, P.F. (1982) Biochem. Pharmacol. 
31, 3673-3682. 
Roberts, D. (1966) Biochemistry 5, 3546-3548. 
Kalman, T.I. and Yalowich, J.C. (1979) in: 
Chemistry and Biology of Pteridines (Kisliuk, R.L. 
and Brown, G.M. eds) pp.671-676, Elsevier, 
Amsterdam, New York. 
231 
Volume 173, number 1 FEBS LETTERS July 1984 
[20] Rode, W., Scanlon, K.J., Moroson, B.A. and 
Bertino, J.R. (1980) J. Biol. Chem. 255, 
1305-1311. 
(211 Balzarini, J. and De Clercq, E. (1984) Biochim. 
Biophys. Acta 785, 36-45. 
[22] Ayusawa, D., Koyama, H., Iwata, K. and Seno, T. 
(1980) Somatic Cell Genet. 6, 261-270. 
[23] Ayusawa, D., Koyama, H., Iwata, K. and Seno, T. 
(1981) Somatic Cell Genet. 7, 523-534. 
[24] Balzarini, J., De Clercq, E., Ayusawa, D. and 
Seno, T. (1984) Biochem. J. 217, 245-252. 
[25] Barr, P.J., Jones, A.S., Serafinowski, P. and 
Walker, R.T. (1978) J. Chem. Sot. Perkin Trans. 
1, 1263-1267. 
[26] De Clercq, E., Descamps, J., De Somer, P., Barr, 
P. J., Jones, A.S. and Walker, R.T. (1979) Proc. 
Natl. Acad. Sci. USA 76, 2947-2951. 
[27] Park, J.S., Chang, C.T.-C., Schmidt, CL., 
Colander, Y., De Clercq, E., Descamps, J. and 
Mertes, M.P. (1980) J. Med. Chem. 23, 661-665. 
[28] Jones, AS., Verhelst, G. and Walker, R.T. (1979) 
Tetrahedron Lett., 4415-4418. 
[29] Swierkowski, M. and Shugar, D. (1969) J. Med. 
Chem. 12, 533-534. 
[30] De Clercq, E. and Shugar, D. (1975) Biochem. 
Pharmacol. 24, 1073-1078. 
[31] Kampf, A., Pillar, C.J., Woodford, W.J. and 
Mertes, M.P. (1976) J. Med. Chem. 19, 909-915. 
[32] De Clercq, E., Descamps, J., Schmidt, C.L. and 
Mertes, M.P. (1979) Biochem. Pharmacol. 28, 
3249-3254. 
[33] Torrence, P.F., Bhooshan, B., Descamps, J. and 
De Clercq, E. (1977) J. Med. Chem. 20, 974-976. 
[34] Schmidt, C.L., Chang, C.T.-C., De Clercq, E., 
Descamps, J. and Mertes, M.P. (1980) J. Med. 
Chem. 23, 252-256. 
[35] De Clercq, E., Descamps, J. and Shugar, D. (1978) 
Antimicrob. Agents Chemother. 13, 545-547. 
[36] Torrence, P.F., Spencer, J.W., Bobst, A.M., 
Descamps, J. and De Clercq, E. (1978) J. Med. 
Chem. 21, 228-231. 
[37] Balzarini, J., De Clercq, E., Torrence, P.F., 
Mertes, M.P., Park, J.S., Schmidt, C.L., Shugar, 
D., Barr, P. J., Jones, A.S., Verhelst, G. and 
Walker, R.T. (1982) Biochem. Pharmacol. 31, 
1089-1095. 
[38] Koyama, H., Ayusawa, D., Tsuji, M. and Seno, T. 
(1982) Mutation Res. 105, 433-438. 
232 
